A Study of Zongertinib Alone or Combined With Other Drugs in People With Breast Cancer or Gastric Gastroesophageal Junction, or Esophageal Cancer

Full Title

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-Label, Multicenter Trial of Oral Zongertinib (BI 1810631) Alone or in Combination with Other Agents for the Treatment of Patients with Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Yelena Janjigian’s office at 646-888-4286.